These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 9145842)

  • 1. Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin.
    Bisognano C; Vaudaux PE; Lew DP; Ng EY; Hooper DC
    Antimicrob Agents Chemother; 1997 May; 41(5):906-13. PubMed ID: 9145842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin.
    Bisognano C; Vaudaux P; Rohner P; Lew DP; Hooper DC
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1428-37. PubMed ID: 10817688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of fibronectin adhesins in quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin or by sigma B transcription factor activity is mediated by two separate pathways.
    Li D; Renzoni A; Estoppey T; Bisognano C; Francois P; Kelley WL; Lew DP; Schrenzel J; Vaudaux P
    Antimicrob Agents Chemother; 2005 Mar; 49(3):916-24. PubMed ID: 15728884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
    Ng EY; Trucksis M; Hooper DC
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of quinolone resistance in Staphylococcus aureus.
    Tanaka M; Wang T; Onodera Y; Uchida Y; Sato K
    J Infect Chemother; 2000 Sep; 6(3):131-9. PubMed ID: 11810552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.
    Fukuda H; Hori S; Hiramatsu K
    Antimicrob Agents Chemother; 1998 Aug; 42(8):1917-22. PubMed ID: 9687384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
    Schmitz FJ; Fluit AC; Brisse S; Verhoef J; Köhrer K; Milatovic D
    FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):281-7. PubMed ID: 10575140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA.
    Muñoz-Bellido JL; Alonzo Manzanares M; Martínez Andrés JA; Guttiérrez Zufiaurre MN; Ortiz G; Segovia Hernández M; García-Rodríguez JA
    Antimicrob Agents Chemother; 1999 Feb; 43(2):354-6. PubMed ID: 9925531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.
    Ince D; Hooper DC
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2755-64. PubMed ID: 11557465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A study on the resistance of Staphylococcus aureus and the mechanisms of its resistance to fluoroquinolone].
    Lei Y; Gui X; Feng G
    Zhonghua Nei Ke Za Zhi; 2001 Mar; 40(3):176-9. PubMed ID: 11798575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. grlA and gyrA mutations and antimicrobial susceptibility in clinical isolates of ciprofloxacin- methicillin-resistant Staphylococcus aureus.
    Coskun-Ari FF; Bosgelmez-Tinaz G
    Eur J Med Res; 2008 Aug; 13(8):366-70. PubMed ID: 18952518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.
    Ferrero L; Cameron B; Crouzet J
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1554-8. PubMed ID: 7492103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureus.
    Sierra JM; Marco F; Ruiz J; Jiménez de Anta MT; Vila J
    Clin Microbiol Infect; 2002 Dec; 8(12):781-90. PubMed ID: 12519351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions.
    Ince D; Hooper DC
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3344-50. PubMed ID: 11083638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of mutations in grlA and gyrA topoisomerase genes with resistance to ciprofloxacin in epidemic and sporadic isolates of methicillin-resistant Staphylococcus aureus.
    Deplano A; Zekhnini A; Allali N; Couturier M; Struelens MJ
    Antimicrob Agents Chemother; 1997 Sep; 41(9):2023-5. PubMed ID: 9303407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
    Strahilevitz J; Hooper DC
    Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.
    Schmitz FJ; Jones ME; Hofmann B; Hansen B; Scheuring S; Lückefahr M; Fluit A; Verhoef J; Hadding U; Heinz HP; Köhrer K
    Antimicrob Agents Chemother; 1998 May; 42(5):1249-52. PubMed ID: 9593159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance.
    Ba BB; Arpin C; Vidaillac C; Chausse A; Saux MC; Quentin C
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1931-6. PubMed ID: 16723548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.